H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Humanigen (HGEN – Research Report) today and set a price target of $28.00. The company's shares closed last Thursday at $1.77, close to its 52-week low of $1.67. According to TipRanks.com, Pantginis is ranked 0 out of 5 stars with an average return of -29.5% and a 19.4% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Bioline RX Ltd Sponsored ADR, and Lineage Cell Therapeutics. Humanigen has an analyst consensus of Moderate Buy, with a price target consensus of $28.00.
https://www.tipranks.com/news/blurbs/h-c-wainwright-reiterates-their-buy-rating-on-humanigen-hgen-2?utm_source=advfn.com&utm_medium=referral
Humanigen (NASDAQ:HGEN)
Historical Stock Chart
From Aug 2022 to Sep 2022 Click Here for more Humanigen Charts.
Humanigen (NASDAQ:HGEN)
Historical Stock Chart
From Sep 2021 to Sep 2022 Click Here for more Humanigen Charts.